Sexually Transmitted Diseases (STD) Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Sexually Transmitted Diseases (STD) Diagnostics Market is projected to expand from USD 103.07 Billion in 2025 to USD 151.33 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.61%. This sector comprises reagents, instruments, and consumables specifically designed to identify pathogens causing infections such as Syphilis, Gonorrhea, and Chlamydia. The market's growth is primarily driven by the rising global prevalence of these infections and the rollout of government initiatives that encourage routine screening to support early intervention and effective treatment.

According to 2025 surveillance data referenced by the American Sexual Health Association, the total number of reported sexually transmitted infections remained 13% higher than levels recorded ten years prior. While this elevated burden fuels demand, the market faces a significant obstacle due to the social stigma surrounding testing. This stigma often discourages individuals from accessing necessary diagnostic services, thereby impeding broader market penetration and adoption.

Market Drivers

The escalating global incidence of sexually transmitted infections acts as a fundamental catalyst for market growth, necessitating a robust testing infrastructure to control outbreaks and prevent long-term complications. The resurgence of bacterial infections, especially in developed regions, compels healthcare systems to acquire increased volumes of molecular and immunoassay-based diagnostic consumables to manage the growing patient load. For instance, the UK Health Security Agency's June 2025 report noted that early-stage syphilis diagnoses in England reached 9,535 cases in 2024, a 2% annual increase, while provisional CDC data from 2025 indicated over 2.2 million total cases of chlamydia, gonorrhea, and syphilis in the United States for the 2024 surveillance period, reinforcing the sustained high demand for diagnostics.

Simultaneously, increasing consumer adoption of at-home and self-collection testing kits is reshaping the diagnostic landscape by decentralizing care and bypassing barriers such as clinical stigma and scheduling logistics. This shift is enabled by regulatory approvals of over-the-counter molecular platforms that provide lab-quality accuracy in private settings. As reported by the FDA in March 2025, the newly authorized Visby Medical Women's Sexual Health Test demonstrated 97.2% accuracy for Chlamydia trachomatis during validation. The availability of high-performance self-tests encourages frequent screening among younger demographics, driving revenue for direct-to-consumer manufacturers and alleviating operational pressure on sexual health clinics.

Market Challenges

Social stigma regarding sexually transmitted diseases constitutes a major restraint on the global diagnostics market by discouraging individuals from seeking timely screening. This psychological barrier, rooted in fear of judgment, embarrassment, or privacy concerns, creates a strong reluctance to visit clinics or utilize testing services. Consequently, a substantial portion of the at-risk population avoids necessary testing, which directly reduces the consumption of diagnostic tests, reagents, and consumables in clinical settings, thereby limiting the addressable market size and restricting revenue generation for manufacturers.

The consequence of this testing gap is highlighted by the disparity between infection estimates and actual diagnostic uptake. According to the World Health Organization, in 2024, more than 1 million sexually transmitted infections were acquired daily worldwide, yet a vast number of these cases remained undiagnosed. This data indicates that despite the availability of testing platforms, the market cannot fully capitalize on the rising prevalence of infections because social apprehension effectively blocks patient entry into the diagnostic ecosystem.

Market Trends

The transition toward Multiplex Nucleic Acid Amplification Tests (NAATs) is fundamentally changing clinical workflows by enabling the simultaneous detection of multiple pathogens from a single patient specimen. This shift toward syndromic panel testing addresses high rates of co-infections, such as chlamydia presenting with gonorrhea, which single-target assays often miss. By consolidating testing into one run, laboratories can reduce turnaround times and operational costs while ensuring comprehensive diagnosis, driving commercial adoption. For example, Hologic, Inc. reported a 9.4% increase in molecular diagnostics revenue in November 2024, largely driven by elevated sales of their multiplex assay for bacterial vaginosis, Candida vaginitis, and Trichomonas vaginalis.

Concurrently, the implementation of Next-Generation Sequencing for genomic surveillance is gaining momentum to combat the escalating threat of antimicrobial resistance in sexually transmitted pathogens. Unlike traditional diagnostics, genomic sequencing allows public health entities to identify specific resistance mutations and track transmission clusters, particularly for Neisseria gonorrhoeae. This capability is essential for tailoring treatment protocols, as highlighted by a November 2025 World Health Organization release which noted that resistance to ceftriaxone and cefixime rose to 5% and 11% respectively between 2022 and 2024, necessitating advanced genomic profiling to manage these resistant strains.

Key Players Profiled in the Sexually Transmitted Diseases (STD) Diagnostics Market

• Becton Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• bioMerieux S.A.
• Abbott Laboratories Inc.
• Danaher Corporation
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• DiaSorin S.p.A
• Bio-Rad Laboratories, Inc.

Report Scope

In this report, the Global Sexually Transmitted Diseases (STD) Diagnostics Market has been segmented into the following categories:

Sexually Transmitted Diseases (STD) Diagnostics Market, by Product:

• Instruments And Services
• Consumables
• Software

Sexually Transmitted Diseases (STD) Diagnostics Market, by Application:

• HIV Testing
• HSV Testing
• CT/NG Testing
• Syphilis Testing
• Gonorrhea Testing
• Others

Sexually Transmitted Diseases (STD) Diagnostics Market, by Technology:

• Immunoassay
• Molecular Diagnostics
• Other

Sexually Transmitted Diseases (STD) Diagnostics Market, by Location Of Testing:

• Laboratory Testing
• Point Of Care Testing
• Others

Sexually Transmitted Diseases (STD) Diagnostics Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sexually Transmitted Diseases (STD) Diagnostics Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.